

Evaluation of the safety of emicizumab prophylaxis in people with haemophilia A: an updated summary of thrombotic events and thrombotic microangiopathies

Authors: Sunita Koparkar,¹ Simona Barlera,² Francis Nissen,³ Richard H. Ko,¹ Guillermo Tobaruela^{3*}

*Email: william.tobaruela@roche.com

Affiliations: ¹Genentech, Inc., South San Francisco, CA, USA; ²Parexel International, Milan, Italy; ³F. Hoffmann-La Roche Ltd, Basel, Switzerland

Summary



An updated safety evaluation of thrombotic events (TEs) and thrombotic microangiopathies (TMAs) was conducted in people with congenital haemophilia A receiving emicizumab



The reporting rate for TEs without concomitant activated prothrombin complex concentrate (aPCC) remains low as exposure increases



The evidence does not support a causal relationship between TEs and emicizumab, and the benefit-risk profile of emicizumab remains positive




All four TMAs identified in this analysis were associated with concomitant aPCC, and no new TMAs have been reported since the previous analysis⁶

Background

- As of March 2022, more than 15,000 people had been treated with emicizumab worldwide, with this number continually growing.¹
- The HAVEN 1-4 trials identified thrombotic events (TEs) and thrombotic microangiopathies (TMAs) as risks when emicizumab is used alongside activated prothrombin complex concentrate (aPCC) at doses of >100U/kg/24 hours for ≥24 hours in people with haemophilia A (HA).²⁻⁵
- Subsequently, these events have been monitored on an ongoing basis in all individuals receiving emicizumab, with or without concurrent aPCC, and routine risk minimisation activities have been included in the label and beyond. This poster presents an updated safety evaluation of emicizumab prophylaxis, focusing on TEs and TMAs.

Methods


Figure 1. Methodology



Results

- As of the data cut-off (15 May 2022), 75 cases (88 events) meeting the search criteria were identified on the Roche Global Safety Database (Figure 2).
- There were 11 clinical trial cases (11 events), 51 post-marketing cases (63 events), and 13 non-interventional study cases (14 events), across approved and unapproved indications, including off-label use.
- Of these, 63 events were identified in people with congenital HA: two TEs and four TMAs associated with aPCC, and 57 TEs not associated with aPCC use.

Figure 2. Summary of TEs and TMA events



No new TEs or TMAs associated with aPCC have been reported since the last analysis (data cut-off 15 May 2021)

- At last analysis, two TEs and four TMAs associated with aPCC were reported;⁶ this updated analysis reports no new aPCC-associated TEs or TMAs.

A total of 49 non-device-associated and non-aPCC-associated TEs were reported in people with congenital HA receiving emicizumab

- Characteristics of non-device-associated and non-aPCC-associated TEs are described in Table 1.
- The median age at event was 48 (range 0.8-84) years.
- A total of 46 (94.0%) TEs were medically confirmed and three (6.0%) were consumer reported; sources included spontaneous (27 TEs), non-interventional studies (10 TEs), literature (8 TEs), and clinical trials (4 TEs).
- Sixteen (32.7%) TEs occurred in people with HA with known FVIII inhibitors.


Table 1. Characteristics of people with congenital HA who experienced non-device-associated TEs

	Non-device-associated TEs N=49
Median (range) age at event, years	48 (0.8-84)*
Medically confirmed, n (%)	46 (93.9)
Consumer reported, n (%)	3 (6.1)
Sources, n (%)	
Post-marketing†	35 (71.4)
Non-interventional study	10 (20.4)
Clinical trial‡	4 (8.2)
Presence of FVIII inhibitors, n (%)	16 (32.7)
Associated with ≥1 CV risk factor§ or other risk factor for thrombosis¶, n (%)	41 (83.7)
Led to discontinuation of emicizumab, n (%)	9 (18.4)
TEs with fatal outcome**, n (%)	4 (8.2)

*Age was provided for 33 events and unknown for nine events. †Post-marketing events include 27 spontaneous events and eight events reported in the literature. ‡Clinical trial events included: three SAEs with acute myocardial infarction (M039129), acute coronary syndrome (B437001), acute myocardial infarction (B437001) and non-serious AE of haemorrhoids thrombosed (S041423). §Previous myocardial infarction, ischaemic heart disease, coronary artery disease, hypertension, hyperlipidaemia, smoking, advanced age. ¶Sepsis/bacteraemia, device use, coinciding injury, hepatitis C, thrombosis. **Two myocardial infarctions in medically complex individuals; two DIC events in people >70 years of age with pneumonia. CV, cardiovascular; DIC, disseminated intravascular coagulation

A total of 23/57 non-aPCC-associated TEs were recovered or resolving at the time of data cut

Figure 4. Reported outcomes of TEs at the time of analysis



A total of 41 non-aPCC-associated TEs were associated with ≥1 CV risk factor or other risk factor for thrombosis*

- All non-aPCC-associated and non-device-associated TEs for which data were available (41/49 events) were associated with a CV or other thrombosis risk factor
 - CV risk factors included previous myocardial infarction, ischaemic heart disease, coronary artery disease, hypertension, hyperlipidaemia, smoking, and advanced age (>50 years)
 - Risk factors for thrombosis included sepsis/bacteraemia, device use, coinciding injury, and hepatitis C infection.
- A total of 27 TEs were associated with ≥3 CV risk factors or other risk factors for thrombosis.

*Risk factors are defined as per Anderson FA, Jr., Spencer FA. 2003⁷ and Mozaffarian D, et al. 2016.⁸

Clinical trial incidence and real-world data analyses

- The incidence rate for serious TEs in clinical trials with people with congenital HA receiving emicizumab is 0.15 events per 100 person-years (95% CI: 0.03-0.44).^{2-5, 9-12}
- Key clinical trials, Phase IV HA studies, and ongoing registries measuring TE frequency include: HAVEN 1-7, STASEY, ATHN 7/ATHN Transcends, EUHASS, PedNET, HEMNOR, and UKHCCO.
- Real-world data in the overall population of people with HA, including incidence risk for arterial, venous and device-related TEs, is shown in Table 2.

Table 2. Real-world data analyses using the Market Scan claims database¹³


Events	Incidence risk, % (95% CI)	Incidence rate/100 person-years (95% CI)
Arterial events		
Myocardial infarction	0.80% (0.53%, 1.12%)	0.23 (0.15, 0.32)
Ischaemic stroke*	1.03% (0.72%, 1.39%)	0.29 (0.20, 0.39)
Venous events		
Deep vein thrombosis*	0.89% (0.60%, 1.23%)	0.25 (0.17, 0.35)
Pulmonary embolism	0.29% (0.14%, 0.49%)	0.08 (0.04, 0.14)
Device-related thrombosis	1.60% (1.21%, 2.05%)	0.46 (0.35, 0.58)

*Excludes device-related thrombosis.

Among people with HA who had dose modification data available and experienced a non-aPCC-associated TE, most had no change to emicizumab prophylaxis

- Emicizumab prophylaxis was modified, interrupted, or withdrawn in 11/57 (19.3%) events of people with HA receiving emicizumab without concomitant aPCC experiencing a TE (Figure 3).
- There were no dose modifications in 21/57 (36.8%) events of people with HA experiencing a non-aPCC-associated TE, and data are unknown for 21 events.

Figure 3. Dose modifications in people with congenital HA who experienced non-aPCC-associated TEs



*One person received 1.5mg/kg emicizumab once per week and then, following two TEs, received 240mg once per week as reported. †TEs with fatal outcome.

Conclusions

- The reporting rate for TEs without concomitant aPCC remains low as emicizumab exposure increases.
- All TMAs were associated with concomitant use of aPCC, and no new TMAs have been reported since the previous analysis.
- Most cases with adequate information available were associated with pre-existing CV risk factors and/or risk factors for thrombosis.
- This analysis continues to support that TEs and TMAs without concomitant aPCC are not an identified risk for people with HA receiving emicizumab prophylaxis. The benefit-risk profile of emicizumab remains positive.

Presented at the 2023 European Association for Haemophilia and Allied Disorders (EAHAD) Annual Meeting | 7-10 February 2023 | Manchester, UK

References

- Emicizumab Global Medical Information Site. Available at: <https://www.emicizumabinfo.global/en/homepage.html>. [Accessed January 2023].
- Oldenburg J, et al. N Engl J Med 2017;377(9):809-18.
- Young G, et al. Blood 2019;134(24):2127-38.
- Mishraji J, et al. N Engl J Med 2018;379(9):811-22.
- Pipe S, et al. Lancet Haematol 2019;6(6):E295-305.
- Howard M, et al. Blood 2021;138(Suppl 1):3186.

- Anderson FA, Jr, Spencer FA. Circulation 2003;107(23 Suppl 1):39-16.
- Mozaffarian D, et al. Circulation 2016;133:e38-360.
- Yang R, et al. Res Pract Thromb Haemost 2022;6:e12670.
- Hermans C, et al. Res Pract Thromb Haemost 2022;6(Suppl 1):e12787.
- Pipe S, et al. Blood 2022;140(Suppl 1):457-9.
- Jimenez-Yuste Y, et al. Res Pract Thromb Haemost 2022;6(8):e12837.
- Faghmous I, et al. J Comp Eff Res 2021;10(18):1323-36.

Acknowledgements

This study was sponsored by F. Hoffmann-La Roche Ltd/Genentech, Inc. The authors would like to thank Monet Howard for her contributions to this analysis. Third party medical writing assistance, under the direction of all authors, was provided by Anna Nagy, BSc, and Jen Evans, BSc, of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd/Genentech, Inc.

Disclosures

SK: employment: Genentech Inc.; shareholder: Genentech Inc.; SB: nothing to disclose; FN: employment: F. Hoffmann-La Roche Ltd; shareholder: F. Hoffmann-La Roche Ltd; RHK: employment: Genentech Inc.; shareholder: Genentech Inc.; GT: employment: F. Hoffmann-La Roche Ltd; shareholder: F. Hoffmann-La Roche Ltd.



Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the lead author of this poster.
Download this presentation: <https://bit.ly/3wvPE8C>